TherapeuticsMD Inc Dossier - Source-backed chat

TherapeuticsMD Inc

TXMDNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.76

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.03Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $23.5M

Enterprise Value $14.3M

Shares Outstanding 11.7M diluted

Moat Rating None

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

TherapeuticsMD has successfully transitioned from a high-burn commercial pharmaceutical company to an asset-light royalty business. By licensing its core products (IMVEXXY, BIJUVA, and ANNOVERA) to Mayne Pharma, the company has eliminated its commercial overhead, R&D expenses, and long-term debt. While this transition has stabilized the balance sheet and narrowed net losses, the company remains cost-absorption constrained due to its small revenue base relative to public company listing costs. The primary investment catalyst is the ongoing evaluation of strategic alternatives, which could result in an acquisition or merger.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Royalty revenues decline due to poor commercial execution by Mayne Pharma or adverse outcomes in ongoing legal disputes. The company fails to secure a strategic transaction, and public company overhead costs gradually deplete cash reserves, raising going-concern risks.

Base CaseCentral scenario

The company continues to collect stable royalty streams from Mayne Pharma, keeping cash burn minimal while actively pursuing a strategic transaction. Net income hovers near break-even, and cash reserves remain stable around $8 million.

Bull CaseUpside scenario

Successful commercialization of IMVEXXY, BIJUVA, and ANNOVERA by Mayne Pharma drives higher-than-expected royalty revenues, while a successful strategic transaction (merger or acquisition) unlocks immediate shareholder value.

Scenarios reflect our research view at the research date.

Key Investment Merits

Asset-light operating model with minimal overhead and no direct commercialization or R&D expenses.
Elimination of long-term commercial debt, resulting in a clean balance sheet with $8.4 million in cash as of Q1 2026.
Active evaluation of strategic alternatives provides a clear catalyst for potential near-term upside.

Key Investment Risks

Complete dependence on Mayne Pharma's commercial execution and success for royalty revenues.
Ongoing legal disputes with Mayne Pharma could disrupt royalty streams or lead to unexpected costs.
Small revenue base may not sustainably support the fixed costs of maintaining a public company structure over the long term.

Thesis Invalidation Triggers

Termination or material negative modification of the Mayne License Agreement.
Formal termination of the strategic alternatives evaluation process without a transaction.
Delisting from the Nasdaq Stock Market due to failure to meet listing requirements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.